Topical olopatadine hydrochloride versus ketotifen fumarate for allergic conjunctivitis

Purpose: Allergic conjunctivitis (AC) is associated with itching, redness, tearing, pain, and burning sensation in the eyes. The inflammatory process is caused by the mechanism of immediate hypersensitivity due to direct contact with the allergen. This process triggers mast cells in the conjunctiva...

Full description

Bibliographic Details
Main Authors: Dharmistha Patel, N Sarala, Narendra Panduranga Datti
Format: Article
Language:English
Published: Knowledge E 2018-01-01
Series:Journal of Ophthalmic & Vision Research
Subjects:
Online Access:http://www.jovr.org/article.asp?issn=2008-322X;year=2018;volume=13;issue=2;spage=119;epage=123;aulast=Patel
_version_ 1811193369425084416
author Dharmistha Patel
N Sarala
Narendra Panduranga Datti
author_facet Dharmistha Patel
N Sarala
Narendra Panduranga Datti
author_sort Dharmistha Patel
collection DOAJ
description Purpose: Allergic conjunctivitis (AC) is associated with itching, redness, tearing, pain, and burning sensation in the eyes. The inflammatory process is caused by the mechanism of immediate hypersensitivity due to direct contact with the allergen. This process triggers mast cells in the conjunctiva to activate and release mediators. The purpose of this study was to compare topical olopatadine and ketotifen in terms of effectiveness and safety for the management of AC. Methods: Patients clinically diagnosed with AC were randomized into two groups of 60 patients each and received either topical olopatadine HCl 0.1% or ketotifen fumarate 0.025%. They were followed up on the 4th, 15th, and 30th days to evaluate symptoms, signs, and quality of life (QOL) scoring. Results: There were a total of 120 patients (67 men and 53 women) with a mean age of 36.35 ± 11 years. Compared to baseline, scores of itching, tearing, redness, eyelid swelling, chemosis and papillae addition of all the individual scores mentioned above and QOL scores reduced significantly (P = 0.001) by the 4th and 15th days of olopatadine and ketotifen application. Compared with ketotifen, olopatadine significantly reduced itching, tearing, hyperemia, and total AC scores by the 4th day (P = 0.001) and conjunctival papillae by the 15th day (P = 0.001). Adverse reactions were reported in 10% and 18% of patients treated with olopatadine and ketotifen, respectively. Conclusion: Compared to ketotifen, olopatadine provided quicker relief of symptoms, and improved symptoms of AC and QOL, with fewer side effects.
first_indexed 2024-04-12T00:07:09Z
format Article
id doaj.art-68fa3cdbc186493ba6c817f01babe73c
institution Directory Open Access Journal
issn 2008-322X
language English
last_indexed 2024-04-12T00:07:09Z
publishDate 2018-01-01
publisher Knowledge E
record_format Article
series Journal of Ophthalmic & Vision Research
spelling doaj.art-68fa3cdbc186493ba6c817f01babe73c2022-12-22T03:56:03ZengKnowledge EJournal of Ophthalmic & Vision Research2008-322X2018-01-0113211912310.4103/jovr.jovr_85_17Topical olopatadine hydrochloride versus ketotifen fumarate for allergic conjunctivitisDharmistha PatelN SaralaNarendra Panduranga DattiPurpose: Allergic conjunctivitis (AC) is associated with itching, redness, tearing, pain, and burning sensation in the eyes. The inflammatory process is caused by the mechanism of immediate hypersensitivity due to direct contact with the allergen. This process triggers mast cells in the conjunctiva to activate and release mediators. The purpose of this study was to compare topical olopatadine and ketotifen in terms of effectiveness and safety for the management of AC. Methods: Patients clinically diagnosed with AC were randomized into two groups of 60 patients each and received either topical olopatadine HCl 0.1% or ketotifen fumarate 0.025%. They were followed up on the 4th, 15th, and 30th days to evaluate symptoms, signs, and quality of life (QOL) scoring. Results: There were a total of 120 patients (67 men and 53 women) with a mean age of 36.35 ± 11 years. Compared to baseline, scores of itching, tearing, redness, eyelid swelling, chemosis and papillae addition of all the individual scores mentioned above and QOL scores reduced significantly (P = 0.001) by the 4th and 15th days of olopatadine and ketotifen application. Compared with ketotifen, olopatadine significantly reduced itching, tearing, hyperemia, and total AC scores by the 4th day (P = 0.001) and conjunctival papillae by the 15th day (P = 0.001). Adverse reactions were reported in 10% and 18% of patients treated with olopatadine and ketotifen, respectively. Conclusion: Compared to ketotifen, olopatadine provided quicker relief of symptoms, and improved symptoms of AC and QOL, with fewer side effects.http://www.jovr.org/article.asp?issn=2008-322X;year=2018;volume=13;issue=2;spage=119;epage=123;aulast=PatelAllergic Conjunctivitis; Ketotifen Fumarate; Olopatadine Hydrochloride
spellingShingle Dharmistha Patel
N Sarala
Narendra Panduranga Datti
Topical olopatadine hydrochloride versus ketotifen fumarate for allergic conjunctivitis
Journal of Ophthalmic & Vision Research
Allergic Conjunctivitis; Ketotifen Fumarate; Olopatadine Hydrochloride
title Topical olopatadine hydrochloride versus ketotifen fumarate for allergic conjunctivitis
title_full Topical olopatadine hydrochloride versus ketotifen fumarate for allergic conjunctivitis
title_fullStr Topical olopatadine hydrochloride versus ketotifen fumarate for allergic conjunctivitis
title_full_unstemmed Topical olopatadine hydrochloride versus ketotifen fumarate for allergic conjunctivitis
title_short Topical olopatadine hydrochloride versus ketotifen fumarate for allergic conjunctivitis
title_sort topical olopatadine hydrochloride versus ketotifen fumarate for allergic conjunctivitis
topic Allergic Conjunctivitis; Ketotifen Fumarate; Olopatadine Hydrochloride
url http://www.jovr.org/article.asp?issn=2008-322X;year=2018;volume=13;issue=2;spage=119;epage=123;aulast=Patel
work_keys_str_mv AT dharmisthapatel topicalolopatadinehydrochlorideversusketotifenfumarateforallergicconjunctivitis
AT nsarala topicalolopatadinehydrochlorideversusketotifenfumarateforallergicconjunctivitis
AT narendrapandurangadatti topicalolopatadinehydrochlorideversusketotifenfumarateforallergicconjunctivitis